Pseudoportomesenteric hypertension (PPMH) is a rare form of non-cirrhotic portal hypertension caused by increased pressure in the portal and mesenteric venous systems. Unlike traditional portal ...

For patients with IIH, sustainable weight loss offers the most effective and lasting relief from symptoms—and can help ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today ...

These disorders should be suspected in young patients with a familyhistory of hypertension who present with severe or refractory hypertension and characteristic hormonal and biochemical abnormalities.

The initial report of monotherapy with the BCL-2 inhibitor venetoclax showed it had durable clinical activity and favorable ...

Hypertension (HTN) increases the risk of heart failure (HF) and it precedes it in 75 percent of cases. This article reviews essential HTN treatment in patients at risk for developing HF.

Shares of CRISPR Therapeutics CRSP have risen 14% over the past month, likely driven by encouraging results from the first ...

Pirtobrutinib (Jaypirca) led to improvements in progression-free survival (PFS) and time to next treatment (TTNT) with a favorable tolerability profile when compared with idelalisib (Zydelig) and ...

There are four stages of hypertension: elevated, stage 1, stage 2, and hypertensive crisis. There are also different types: primary, secondary, resistant, malignant ...

Regulatory Clearances Support Glaukos' Plans to Advance and Accelerate its Interventional Glaucoma Initiatives Globally Marks ...

New CAR T-cell therapy shows remarkable efficacy in treating relapsed multiple myeloma, achieving high response rates and ...